{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}],"title":"Very good partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}],"title":"Complete Response/Stringent complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Progressive Disease/no response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Defined as maximum depth of response (ranging from partial response to complete response by International Myeloma Working Group (IMWG) criteria at any point during post-induction maintenance therapy.\n\nIMWG: Complete Response (CR): negative immunofixation on the serum and urine, no soft tissue plasmacytomas and \\<5% plasma cells in the bone marrow; stringent CR: CR+normal free light chain ratio, no clonal cells in bone marrow by immunohistochemistry or immunofluorescence; Very Good Partial Response: serum and urine M-protein detected by immunofixation but not electrophoresis, \\>90% in serum M-protein+urine, M-protein level \\<100 mg/24hour; Partial Response (PR): ≥50% decrease of serum and M-protein, 24 hour urinary M-protein decrease by ≥90% or \\<200 mg/24hour. Stable disease mean that the patient has not achieved CR, VGPR, PR or progressive disease.","groups":[{"description":"INDUCTION (28-day cycles for 8 cycles):\n\n* VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15\n* Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15\n* Dexamethasone 40 mg PO days 1,8 and 15\n\nMAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):\n\n* Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21\n* Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15\n\nVelcade: Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \\[10,12,14, etc.\\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until","id":"OG000","title":"Velcade, Cyclophosphamide, Revlimid"}],"paramType":"NUMBER","populationDescription":"8 of all subjects reached maintenance and could be analyzed","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Maximum Depth of Response During Maintenance Therapy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}